Microbot Medical Stock Gross Profit
| CY9D Stock | 0.91 0.02 2.15% |
Microbot Medical fundamentals help investors to digest information that contributes to Microbot Medical's financial success or failures. It also enables traders to predict the movement of Microbot Stock. The fundamental analysis module provides a way to measure Microbot Medical's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Microbot Medical stock.
Microbot |
Microbot Medical Company Gross Profit Analysis
Microbot Medical's Gross Profit is the most basic measure of business operational efficiency. It is simply the difference between sales revenue and the cost associated with making a product or providing a service. It is calculated before deducting administrative expenses, taxes, and interest payments.
Gross Profit varies significantly from one sector to another and tells an investor how much money a business would have made if it didn't have to pay any overhead expenses such as salary, taxes, or rent.
| Competition |
According to the company disclosure, Microbot Medical reported 0.0 of gross profit. This indicator is about the same for the average (which is currently at 0.0) sector and about the same as Gross Profit (which currently averages 0.0) industry. This indicator is about the same for all Germany stocks average (which is currently at 0.0).
Microbot Gross Profit Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Microbot Medical's direct or indirect competition against its Gross Profit to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Microbot Medical could also be used in its relative valuation, which is a method of valuing Microbot Medical by comparing valuation metrics of similar companies.Microbot Medical is currently under evaluation in gross profit category among its peers.
Microbot Fundamentals
| Current Valuation | 25.72 M | |||
| Price To Book | 5.80 X | |||
| EBITDA | (11.28 M) | |||
| Net Income | (11.31 M) | |||
| Cash Flow From Operations | (9.35 M) | |||
| Market Capitalization | 30.34 M | |||
| Total Asset | 16.77 M | |||
| Net Asset | 16.77 M |
About Microbot Medical Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Microbot Medical's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Microbot Medical using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Microbot Medical based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Microbot Stock Analysis
When running Microbot Medical's price analysis, check to measure Microbot Medical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Microbot Medical is operating at the current time. Most of Microbot Medical's value examination focuses on studying past and present price action to predict the probability of Microbot Medical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Microbot Medical's price. Additionally, you may evaluate how the addition of Microbot Medical to your portfolios can decrease your overall portfolio volatility.